Country Club Bank GFN Grows Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Country Club Bank GFN increased its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 40.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 80,501 shares of the company’s stock after buying an additional 23,341 shares during the period. Johnson & Johnson comprises 1.3% of Country Club Bank GFN’s portfolio, making the stock its 15th largest holding. Country Club Bank GFN’s holdings in Johnson & Johnson were worth $13,245,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. DORCHESTER WEALTH MANAGEMENT Co lifted its holdings in shares of Johnson & Johnson by 8.6% in the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after purchasing an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P lifted its holdings in shares of Johnson & Johnson by 88.9% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after purchasing an additional 82,429 shares in the last quarter. AMI Investment Management Inc. lifted its holdings in shares of Johnson & Johnson by 8.8% in the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after purchasing an additional 1,475 shares in the last quarter. Equitable Holdings Inc. lifted its holdings in shares of Johnson & Johnson by 4.9% in the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after purchasing an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd raised its position in shares of Johnson & Johnson by 2.4% in the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after buying an additional 20,528 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 76,923 shares of the company’s stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the transaction, the executive vice president now directly owns 126,456 shares in the company, valued at $22,354,891.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Jennifer L. Taubert sold 76,923 shares of the company’s stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the transaction, the executive vice president now directly owns 126,456 shares in the company, valued at $22,354,891.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Ashley Mcevoy sold 73,323 shares of the company’s stock in a transaction on Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the completion of the transaction, the executive vice president now owns 41,813 shares of the company’s stock, valued at $7,336,927.11. The disclosure for this sale can be found here. Insiders sold 277,886 shares of company stock valued at $48,550,549 over the last 90 days. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $172.36 on Wednesday. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company has a 50 day moving average price of $176.30 and a 200 day moving average price of $171.39. The firm has a market capitalization of $450.63 billion, a price-to-earnings ratio of 24.01, a price-to-earnings-growth ratio of 3.28 and a beta of 0.56. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company had revenue of $23.79 billion during the quarter, compared to analyst estimates of $23.44 billion. During the same quarter in the prior year, the business earned $2.60 earnings per share. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. Sell-side analysts anticipate that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.62%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s payout ratio is currently 62.95%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Sanford C. Bernstein cut their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Raymond James cut their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Atlantic Securities cut their price objective on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. StockNews.com assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Finally, Citigroup boosted their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Seven analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $182.42.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.